Pertzye (pancrelipase) / Chiesi - LARVOL DELTA

Changes in Medicaid claims for chronic medications for cystic fibrosis (NACFC 2025) - "Background: Several published reports have described changes in chronic medications for cystic fibrosis (CF) after the initiation of elexacaftortezacaftor-ivacaftor (ETI)...Prescriptions for inhaled tobramycin were difficult to differentiate from prescriptions for IV tobramycin, so we have not yet included tobramycin in our analysis... Prescriptions for dornase alfa and inhaled aztreonam decreased after the introduction of ETI, but to a greater extent than recorded in the CFFPR (approximately 15% and 25%, respectively). These results support the use of claims data to complement CFFPR analyses and prospective studies to understand changes in chronic CF medications use after ETI. Our analysis is limited by the inability to examine only people with CF, to determine if people with CF took the medications that were prescribed, or whether changes in medications occurred via shared decision-making with the CF care team."

Medicaid • Reimbursement • US reimbursement • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - P1/2 | N=17 | Active, not recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Recruiting ➔ Active, not recruiting | N=40 ➔ 17

Enrollment change • Enrollment closed • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2024 ➔ Nov 2025 | Trial primary completion date: Nov 2024 ➔ Nov 2025

Trial completion date • Trial primary completion date • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Mitigating Financial Toxicity of Pancreatic Enzyme Replacement Therapy in Medicare Part D (ACG 2024) - "Total MPD PERT spending was $1.67 billion; Creon spending was $1.31 billion (78%). Alternative supply at Amazon and GoodRx price-point was constitutively unfavorable, mean relative cost 1.34 and 1.38 respectively. Zenpep was also unfavorable at VHA price-point; although others yielded potential cost savings."

Medicare • Reimbursement • US reimbursement • Gastroenterology • Pancreatitis

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2023 ➔ Nov 2024 | Trial primary completion date: Nov 2023 ➔ Nov 2024

Metastases • Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center

New P1/2 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer (clinicaltrials.gov) - P1/2; N=16; Terminated; Sponsor: Massimo Raimondo, M.D.; N=30 ➔ 16; Recruiting ➔ Terminated; Study was terminated due to difficulty in recruiting subjects.

Clinical • Enrollment change • Trial termination • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor